Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

Dasatinib Plus Blinatumomab Increases Response and MRD Negativity in Ph-Positive Acute Lymphocytic Leukemia

Combining the second-generation tyrosine kinase inhibitor (TKI) dasatinib with the bispecific monoclonal antibody blinatumomab induced high response rates in adult patients with Philadelphia chromosome...
On location

Gilteritinib Outperforms Standard Chemotherapy in FLT3-Mutated AML, Regardless of Mutation Burden

According to an analysis from the phase III ADMIRAL trial, treatment with gilteritinib was associated with higher response rates and longer survival than chemotherapy...
On location

Evaluating PRM-151 in Patients With Myelofibrosis Resistant or Intolerant to Ruxolitinib

According to results from a double-blind, phase II study, PRM-151 improved bone marrow fibrosis grade, transfusion dependence, and symptoms in a cohort of patients...
On location

Should Guadecitabine Be the HMA of Choice in Acute Myeloid Leukemia?

Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients with treatment-naïve acute myeloid leukemia (AML) suggest that this...
On location

Can Women With CML Safely Continue TKIs During Pregnancy?

Most women with chronic myeloid leukemia (CML) who received treatment with tyrosine kinase inhibitors (TKIs) and became pregnant had a normal childbirth, with no...
On location

Nivolumab Associated With High Response Rates in Relapsed/Refractory PMBL

Nearly three-quarters of patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBL) responded to treatment with nivolumab plus brentuximab vedotin, according to findings presented...
On location

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single agent improved progression-free survival (PFS) compared with idelalisib or...
On location

New Subcutaneous Daratumumab Formulation Overcomes Infusion Barrier for Patients

Daratumumab-based regimens have shown efficacy across all lines of therapy in multiple myeloma (MM), but the agent requires a long intravenous infusion time, lasting...
On location

Exploring Safety and Efficacy of 5F9 and Azacitidine in AML and MDS

Watch our interview with David Sallman, MD.In initial results from a phase Ib trial presented at the 2019 American Society of Clinical Oncology annual...
On location

Iberdomide: A New Immunomodulatory Drug for Heavily Refractory Myeloma

One-third of patients with relapsed/refractory multiple myeloma (MM) responded to treatment with the investigational agent iberdomide, according to early results from a first-in-human trial. Sagar...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.